Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study
Clinical trial NCT04762030 · UNKNOWN
Trial details
- NCT number
- NCT04762030
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-08
- Primary completion
- 2023-12-30
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.